Although hypertension is present in 25–50% of patients with hypertrophic cardiomyopathy (HCM), its clinical characterization and prognostic implications in this population remain insufficiently investigated.(1)
To describe the phenotype of hypertensive patients with HCM using cardiovascular magnetic resona...
J. Florence, T. Goncalves, S. Toupin et al.· European Heart Journal· 0 citations
Although prognosis in hypertrophic cardiomyopathy (HCM) differs between women and men, sex-related differences regarding cardiovascular magnetic resonance (CMR) features, especially late gadolinium enhancement (LGE), remains poorly studied.
To assess the sex-related prognostic value of the “LGE granularity...
F. Abadie, J. Florence, Y. Bohbot et al.· European Heart Journal· 0 citations
Sudden cardiac death (SCD) remains a major cause of mortality in ischemic cardiomyopathy (ICM). Current guidelines recommend implantable cardioverter-defibrillator (ICD) implantation mainly based on left ventricular ejection fraction (LVEF), which has limited specificity for arrhythmic events. Cardiovascular magn...
A. Unger, A. Pavon, J. Amar et al.· European Heart Journal· 0 citations
In this large multicenter cohort of end-stage HCM patients, the LGE granularity model integrating the LGE extent, location, and pattern provided strong and independent prognostic value beyond traditional prognostic factors.
J. Hudelo, J. Garot, S. Toupin et al.· European Heart Journal· 0 citations
Cardiovascular disease and cancer are the two leading causes of mortality worldwide. (1) Advances in oncologic therapies have improved cancer survival, resulting in a growing population of patients with active malignancy or cancer survivors who remain at increased risk of cardiovascular and non-cancer mortality....
A. Afana, S. Duhamel, S. Toupin et al.· European Heart Journal· 0 citations
In patients with early-stage TNBC treated with pembrolizumab, cardiotoxicity was frequent and associated with a significant reduction in overall survival, and larger prospective studies are required to better characterise predictors of cardiotoxicity in this setting.
L. Dib, B. Sibila, C. Regragui et al.· European Heart Journal, Supp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.